FDMT Q1 2019 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-12.9% YoY

Gross Profit

-$6M-284.6% margin

Operating Income

-$9M-395.2% margin

Net Income

-$8M-374.0% margin

EPS (Diluted)

$-1.61

QoQ Revenue Growth

-51.3%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$736,000

Balance Sheet

Total Assets

$81M

Total Liabilities

$9M

Stockholders' Equity

$61M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-12.9%
Gross Profit	-$6M	-$2M	-300.4%
Operating Income	-$9M	-$3M	-227.0%
Net Income	-$8M	-$3M	-218.5%